Which has better earnings and valuation, KALA or INAB?

IN8bio is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$96.14 N/A IN8bio N/A N/A -$19.44M -$2.61 N/A

Is KALA or INAB more profitable?

IN8bio's return on equity of -96.39% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -1,336.10% -94.85% IN8bio N/A -96.39% -80.18%

Is INAB or XLO more profitable?

IN8bio has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. IN8bio's return on equity of -96.39% beat Xilio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -96.39% -80.18% Xilio Therapeutics -58.52% -151.42% -27.61%

Which has better earnings & valuation, IMMP or INAB?

IN8bio has lower revenue, but higher earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $6.69M 8.24 -$39.78M N/A N/A IN8bio N/A N/A -$19.44M -$2.61 N/A

Is IMMP or INAB more profitable?

Prima BioMed's return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A IN8bio N/A -96.39% -80.18%

Does the media prefer IMMP or INAB?

In the previous week, Prima BioMed had 10 more articles in the media than IN8bio. MarketBeat recorded 11 mentions for Prima BioMed and 1 mentions for IN8bio. Prima BioMed's average media sentiment score of 0.12 beat IN8bio's score of 0.00 indicating that Prima BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IN8bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer INCR or INAB?

IN8bio has a consensus price target of $4.00, suggesting a potential upside of 179.72%. Given IN8bio's stronger consensus rating and higher possible upside, analysts clearly believe IN8bio is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, INCR or INAB?

InterCure has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InterCure $270.20M 0.19 -$10.37M $0.03 30.96 IN8bio N/A N/A -$19.44M -$2.61 N/A

Is INCR or INAB more profitable?

InterCure's return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A IN8bio N/A -96.39% -80.18%

Does the media prefer INCR or INAB?

In the previous week, InterCure had 1 more articles in the media than IN8bio. MarketBeat recorded 2 mentions for InterCure and 1 mentions for IN8bio. InterCure's average media sentiment score of 1.00 beat IN8bio's score of 0.00 indicating that InterCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InterCure 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IN8bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is INAB or CRVO more profitable?

IN8bio has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. IN8bio's return on equity of -96.39% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -96.39% -80.18% CervoMed -672.80% -136.08% -112.62%

Does the media favor INAB or CRVO?

In the previous week, CervoMed had 21 more articles in the media than IN8bio. MarketBeat recorded 22 mentions for CervoMed and 1 mentions for IN8bio. CervoMed's average media sentiment score of 0.42 beat IN8bio's score of 0.00 indicating that CervoMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IN8bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CervoMed 4 Very Positive mention(s) 2 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

IN8bio (INAB) Competitors

$1.43 -0.04 (-2.72%)

Closing price 04:00 PM Eastern

Extended Trading

$1.44 +0.01 (+0.70%)

As of 04:10 PM Eastern

Compare

INAB vs. KALA, XLO, IMMP, INCR, and CRVO

Should you buy IN8bio stock or one of its competitors? MarketBeat compares IN8bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IN8bio include KALA BIO (KALA), Xilio Therapeutics (XLO), Prima BioMed (IMMP), InterCure (INCR), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry.

How does IN8bio compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

KALA BIO currently has a consensus price target of $1,018.75, indicating a potential upside of 28,120.22%. IN8bio has a consensus price target of $4.00, indicating a potential upside of 179.72%. Given KALA BIO's higher possible upside, research analysts plainly believe KALA BIO is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, IN8bio had 1 more articles in the media than KALA BIO. MarketBeat recorded 1 mentions for IN8bio and 0 mentions for KALA BIO. KALA BIO's average media sentiment score of 0.00 equaled IN8bio'saverage media sentiment score.

Company	Overall Sentiment
KALA BIO	Neutral
IN8bio	Neutral

IN8bio's return on equity of -96.39% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
IN8bio	N/A	-96.39%	-80.18%

KALA BIO has a beta of -2.4, meaning that its share price is 340% less volatile than the broader market. Comparatively, IN8bio has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

IN8bio is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by insiders. Comparatively, 14.5% of IN8bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

IN8bio beats KALA BIO on 8 of the 10 factors compared between the two stocks.

How does IN8bio compare to Xilio Therapeutics?

IN8bio (NASDAQ:INAB) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

IN8bio presently has a consensus price target of $4.00, suggesting a potential upside of 179.72%. Xilio Therapeutics has a consensus price target of $28.00, suggesting a potential upside of 218.54%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Xilio Therapeutics is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

IN8bio has higher earnings, but lower revenue than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A
Xilio Therapeutics	$53.48M	1.08	-$35.04M	-$3.55	N/A

IN8bio has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. IN8bio's return on equity of -96.39% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-96.39%	-80.18%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

IN8bio has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

In the previous week, IN8bio had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 1 mentions for IN8bio and 0 mentions for Xilio Therapeutics. IN8bio's average media sentiment score of 0.00 equaled Xilio Therapeutics'average media sentiment score.

Company	Overall Sentiment
IN8bio	Neutral
Xilio Therapeutics	Neutral

92.1% of IN8bio shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 14.5% of IN8bio shares are owned by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

IN8bio beats Xilio Therapeutics on 10 of the 15 factors compared between the two stocks.

How does IN8bio compare to Prima BioMed?

Prima BioMed (NASDAQ:IMMP) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

IN8bio has lower revenue, but higher earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69M	8.24	-$39.78M	N/A	N/A
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A

In the previous week, Prima BioMed had 10 more articles in the media than IN8bio. MarketBeat recorded 11 mentions for Prima BioMed and 1 mentions for IN8bio. Prima BioMed's average media sentiment score of 0.12 beat IN8bio's score of 0.00 indicating that Prima BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IN8bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prima BioMed's return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
IN8bio	N/A	-96.39%	-80.18%

Prima BioMed has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, IN8bio has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Prima BioMed presently has a consensus target price of $5.50, indicating a potential upside of 1,369.80%. IN8bio has a consensus target price of $4.00, indicating a potential upside of 179.72%. Given Prima BioMed's higher possible upside, equities research analysts plainly believe Prima BioMed is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 3.1% of Prima BioMed shares are held by insiders. Comparatively, 14.5% of IN8bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Prima BioMed beats IN8bio on 7 of the 10 factors compared between the two stocks.

How does IN8bio compare to InterCure?

InterCure (NASDAQ:INCR) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

8.3% of InterCure shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 0.2% of InterCure shares are held by insiders. Comparatively, 14.5% of IN8bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

InterCure has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$270.20M	0.19	-$10.37M	$0.03	30.96
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A

In the previous week, InterCure had 1 more articles in the media than IN8bio. MarketBeat recorded 2 mentions for InterCure and 1 mentions for IN8bio. InterCure's average media sentiment score of 1.00 beat IN8bio's score of 0.00 indicating that InterCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InterCure	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IN8bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InterCure has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, IN8bio has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market.

IN8bio has a consensus price target of $4.00, suggesting a potential upside of 179.72%. Given IN8bio's stronger consensus rating and higher possible upside, analysts clearly believe IN8bio is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

InterCure's return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
IN8bio	N/A	-96.39%	-80.18%

Summary

InterCure beats IN8bio on 9 of the 14 factors compared between the two stocks.

How does IN8bio compare to CervoMed?

IN8bio (NASDAQ:INAB) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

IN8bio currently has a consensus target price of $4.00, indicating a potential upside of 179.72%. CervoMed has a consensus target price of $22.60, indicating a potential upside of 433.02%. Given CervoMed's stronger consensus rating and higher probable upside, analysts plainly believe CervoMed is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

92.1% of IN8bio shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 14.5% of IN8bio shares are owned by company insiders. Comparatively, 35.8% of CervoMed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

IN8bio has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market. Comparatively, CervoMed has a beta of -0.68, indicating that its stock price is 168% less volatile than the broader market.

In the previous week, CervoMed had 21 more articles in the media than IN8bio. MarketBeat recorded 22 mentions for CervoMed and 1 mentions for IN8bio. CervoMed's average media sentiment score of 0.42 beat IN8bio's score of 0.00 indicating that CervoMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IN8bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CervoMed	4 Very Positive mention(s)	2 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

IN8bio has higher earnings, but lower revenue than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A
CervoMed	$4.01M	9.79	-$26.97M	-$3.28	N/A

IN8bio has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. IN8bio's return on equity of -96.39% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-96.39%	-80.18%
CervoMed	-672.80%	-136.08%	-112.62%

Summary

IN8bio beats CervoMed on 8 of the 15 factors compared between the two stocks.

Get IN8bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INAB vs. The Competition

Export

Metric	IN8bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.08M	$3.39B	$6.40B	$12.59B
Dividend Yield	N/A	2.27%	2.67%	5.69%
P/E Ratio	-0.55	19.56	24.51	24.45
Price / Sales	N/A	325.83	553.78	123.18
Price / Cash	N/A	125.35	43.94	55.48
Price / Book	0.51	8.16	10.70	6.58
Net Income	-$19.44M	$23.89M	$3.57B	$337.29M
7 Day Performance	-0.69%	2.55%	0.56%	0.55%
1 Month Performance	0.70%	4.97%	3.57%	4.43%
1 Year Performance	-32.86%	53.51%	28.49%	31.16%

IN8bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INAB IN8bio	3.3808 of 5 stars	$1.43 -2.7%	$4.00 +179.7%	-31.3%	$14.08M	N/A	N/A	20	Short Interest Decrease Gap Down
KALA KALA BIO	1.8042 of 5 stars	$2.94 +11.4%	$1,018.75 +34,551.4%	-98.6%	$54.66M	N/A	N/A	30	Short Interest Increase
XLO Xilio Therapeutics	2.0761 of 5 stars	$8.25 -1.1%	$28.00 +239.4%	-6.0%	$54.29M	$43.77M	N/A	70	Analyst Upgrade
IMMP Prima BioMed	2.3989 of 5 stars	$0.36 -1.7%	$5.50 +1,411.0%	-77.5%	$53.64M	$6.69M	N/A	2,021	Analyst Upgrade
INCR InterCure	1.3965 of 5 stars	$0.97 +1.2%	N/A	-37.4%	$52.82M	$78.47M	32.20	350

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INAB) was last updated on 6/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IN8bio (INAB) Competitors